Open AccessBotulin Toxin Use in Rosacea and Facial Flushing Treatment
Author(s) -
Jacopo Scala,
Aleksandra Vojvodić,
Petar Vojvodić,
Tatjana Vlaskovic-Jovicevic,
Zorica Perić-Hajzler,
Dušica Matović,
Sanja Dimitrijevic,
Jovana Vojvodić,
Goran Šijan,
Nenad Stepić,
Uwe Wollina,
Michael Tirant,
Nguyễn Văn Thường,
Massimo Fioranelli,
Torello Lotti
Publication year - 2019
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2019.784
Subject(s) - medicine , rosacea , calcitonin gene related peptide , acetylcholine , botulinum toxin , clostridium botulinum , neuromuscular junction , vasodilation , flushing , pharmacology , anesthesia , dermatology , toxin , neuropeptide , endocrinology , receptor , microbiology and biotechnology , neuroscience , acne , biology
Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of muscular/neuromuscular conditions and more recently also for cosmetic use.
BTX has experimented in some dermatological conditions, which include Rosacea and facial flushing treatment with good results. The complex mechanism underlying those results is not completely understood but was proposed a release inhibition of acetylcholine from peripheral autonomic nerves of the cutaneous vasodilatory system combined with the blockade substance P and calcitonin gene-related peptide (CGRP) thus modulating blood vessel dilatation.
We analysed the published data on BTX off label applications rosacea and flushing retrieved from PubMed.